Pagets Disease

Cannabinoids use in Bone Disease

The endocannabinoid system plays an important role in numerous physiological processes and represents a potential drug target for diseases ranging from brain disorders to cancer. Recent preclinical studies implicated endocannabinoids and their receptors in the regulation of bone cell activity and in the pathogenesis of bone loss. Cells and intervening nerves in the skeleton express cannabinoid receptors and the machinery for the synthesis and breakdown of endocannabinoids. In healthy adult mice, pharmacological and genetic inactivation of the cannabinoid type 1 receptor (CB1) and putative cannabinoid receptor GPR55 (G protein-coupled receptor 55) inhibit osteoclastic bone resorption and increase bone mass, suggesting that both receptors have a negative role in early bone development.

• The promise and dilemma of cannabinoid therapy: lessons from animal studies of bone disease
• Differential transcriptional profiles mediated by exposure to the cannabinoids CBD and THC in BV-2 microglial cells
• Patent application for the use of cannabinoids in Pagets Disease